Johnson & Johnson's HIV vaccine candidate has failed its first major efficacy test, as it was unable to protect women against infection with the virus in a phase 2b trial carried out in sub ...

The first human clinical trials testing a new strategy to protect against HIV infections have yielded promising early results ...

Worldwide, an estimated 40 million people live with HIV. Two-thirds of this group are on the African continent. In 2023, more ...

Worldwide, an estimated 40 million people live with HIV. Two-thirds of this group on the African continent. In 2023, more ...

Anti-HIV mRNA vaccines are already in development, some in early-stage human trials. There is no evidence that mRNA vaccines can alter human DNA. Yes, an mRNA vaccine might well work against HIV, and ...

Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine ...

A team of researchers funded by the National Institutes of Health analyzed the safety and tolerability of three investigational HIV-1 trimer mRNA vaccines: BG505 MD39.3 gp140 (soluble trimer gp140 ...

May 16 (Reuters) - (To receive the full newsletter in your inbox for free sign up here) The first human clinical trials testing a new strategy to protect against HIV infections have yielded ...